Notice: This company has been marked as potentially delisted and may not be actively trading. PhaseBio Pharmaceuticals (PHAS) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period MedPharm appoints Bill Humphries as new CEOFebruary 6, 2025 | msn.comPhaseBio Pharmaceuticals Inc.October 19, 2024 | thestreet.comPhiladelphia-area life sciences industry nears 900 layoffs since 2022October 11, 2024 | bizjournals.comPhaseBio Pharmaceuticals, Inc. (PHASQ)August 3, 2024 | ca.finance.yahoo.comVelia Therapeutics Appoints Michael York as Chief Business OfficerDecember 14, 2023 | finance.yahoo.comAlcami Announces CEO TransitionJune 5, 2023 | finance.yahoo.com8-K: PhaseBio Pharmaceuticals IncMay 12, 2023 | marketwatch.comAbsci Corporation: Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating ResultsMarch 31, 2023 | finanznachrichten.deBioCryst Pharmaceuticals, Inc.: BioCryst Appoints Dr. Nancy Hutson as Chair of the BoardMarch 31, 2023 | finanznachrichten.deBioCryst Appoints Dr. Nancy Hutson as Chair of the BoardMarch 31, 2023 | finance.yahoo.comCardiomyopathy Medication Market Size and Forecast till 2031March 22, 2023 | marketwatch.comCardiomyopathy Medication Market Emerging Demand and Drive Growth by 2028 with Top Countries DataFebruary 28, 2023 | marketwatch.comSFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio PharmaceuticalsJanuary 17, 2023 | benzinga.comBankruptcy court approves PhaseBio's $32.9M asset transfer dealJanuary 5, 2023 | bizjournals.comBankrupt PhaseBio Identifies Chiesi as Lead Bidder for Bentracimab AssetsNovember 8, 2022 | marketwatch.comShort Volatility Alert: PhaseBio Pharmaceuticals, Inc.November 4, 2022 | benzinga.comWhy Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day SessionNovember 2, 2022 | msn.comWhy Goodyear Tire & Rubber Shares Are Trading Lower; Here Are 24 Stocks Moving PremarketNovember 1, 2022 | msn.comPhaseBio Pharmaceuticals 10% Owner Trades Company's StockOctober 27, 2022 | benzinga.comPhaseBio Files for Bankruptcy Following Blackstone-Backed Partner’s LawsuitOctober 25, 2022 | wsj.comPhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $100MOctober 25, 2022 | bizjournals.comPhaseBio Pharma Files For Chapter 11 Bankruptcy ProtectionOctober 24, 2022 | nasdaq.comPhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy CodeOctober 24, 2022 | finance.yahoo.comPhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $60MOctober 24, 2022 | finance.yahoo.comPhaseBio Files for Bankruptcy With Plans to Sell AssetsOctober 24, 2022 | finance.yahoo.comCash-strapped PhaseBio sued by drug development partner in dispute over experimental therapyOctober 19, 2022 | bizjournals.comPhaseBio Might Have To Return Global Rights To Its Lead ProgramOctober 6, 2022 | finance.yahoo.comHypertension Clinical Trials Pipeline Analysis: 90+ Companies are Working to Improve the Treatment Space | DelveInsightOctober 3, 2022 | finance.yahoo.comWhy an East Bay company wants control of its partner's blood thinner antidoteSeptember 29, 2022 | finance.yahoo.comPhaseBio sinks ~67% after getting transfer notice for lead drug bentracimab's businessSeptember 28, 2022 | seekingalpha.comPhaseBio Pharmaceuticals (PHAS) Investor Presentation - SlideshowAugust 14, 2022 | seekingalpha.comPhaseBio Pharmaceuticals (PHAS) Reports Q2 Loss, Lags Revenue EstimatesAugust 12, 2022 | finance.yahoo.comPhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business HighlightsAugust 12, 2022 | finance.yahoo.comPulmonary Hypertension Clinical Trials Pipeline Offers Promising Novel Treatment Options | DelveInsightAugust 1, 2022 | finance.yahoo.comStrong week for PhaseBio Pharmaceuticals (NASDAQ:PHAS) shareholders doesn't alleviate pain of three-year lossJuly 9, 2022 | finance.yahoo.comPhaseBio Pharmaceuticals: Q1 Earnings InsightsMay 16, 2022 | benzinga.comPhaseBio Pharmaceuticals GAAP EPS of -$0.23 beats by $0.43May 16, 2022 | seekingalpha.comPhaseBio to seek FDA approval for clotting agent in 4Q 2022May 16, 2022 | seekingalpha.comPhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business HighlightsMay 16, 2022 | finance.yahoo.comPhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue EstimatesMay 16, 2022 | finance.yahoo.comPHAS PhaseBio Pharmaceuticals, Inc.May 14, 2022 | seekingalpha.comNeedham Estimates PhaseBio Pharma's Bentracimab Market Opportunity Of Up To $1.5BApril 18, 2022 | finance.yahoo.comPhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare ConferenceApril 7, 2022 | nz.finance.yahoo.comPhaseBio reports full results of phase 2b trial of bentracimab to reverse ticagrelor's antiplatelet activityApril 4, 2022 | seekingalpha.comPhaseBio Announces Positive Results from Phase 2b Trial for BentracimabApril 4, 2022 | finance.yahoo.comPhaseBio Pharmaceuticals (NASDAQ:PHAS) Price Target Cut to $10.00Needham & Company LLC dropped their price target on shares of PhaseBio Pharmaceuticals from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Monday.March 28, 2022 | marketbeat.comNeedham Maintains Buy on PhaseBio Pharmaceuticals, Lowers Price Target to $10March 28, 2022 | benzinga.comLooking Into PhaseBio Pharmaceuticals's Return On Capital EmployedMarch 25, 2022 | benzinga.comPhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business HighlightsMarch 24, 2022 | finance.yahoo.comPhaseBio Pharmaceuticals Announces Bentracimab Manufacturing UpdateMarch 8, 2022 | finance.yahoo.com Get PhaseBio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAS and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAS Media Mentions By Week PHAS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHAS News Sentiment▼0.000.61▲Average Medical News Sentiment PHAS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHAS Articles This Week▼00▲PHAS Articles Average Week Get PhaseBio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PHIO News Today NERV News Today TRIB News Today CLRB News Today IPA News Today IMNN News Today BCDA News Today BCTX News Today OMGA News Today ACXP News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHAS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PhaseBio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PhaseBio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHAS Stock Alerts